Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Diaxonhit [ALEHT] ::.

Diaxonhit group resulted from the merger of Exonhit and Ingen Biosciences on December 14th, 2012. This new company has a dual business model dedicated to diagnostics. Diaxonhit has a portfolio of more than 700 diagnostic products and related devices distributed through exclusive agreements in France, Belgium and Switzerland. With its R&D team, Diaxonhit also capitalizes on its proprietary human Genome Wide Splice Array technology to identify the molecular signature of pathologies. These molecular signatures can then be used to design innovative diagnostic products.

The development of innovative diagnostic tests represents the main value driver of Diaxonhit. As of January 2015, Diaxonhit successfully developed BJI Inoplex for prosthetic joint infection diagnosis (launch expected Q1-2015). Dx15 for thyroid cancer diagnosis is currently under clinical validation with a CE marking expected in Q4-2016. Diaxonhit also joined the PROTHEVIH consortium, and will develop two diagnostic tests for HIV. Diaxonhit also licensed AlloMap from the US company CareDx. This CE-marked test aims to monitor heart transplant rejection.

We initiated Diaxonhit’s coverage in 2013 and will conduct regular analyses. These analyst reports are freely available for download on the links below.